SIR of HL by histology in a first-degree relative of an HL patient in 5 Nordic countries
| Relative’s histology . | HL patient in the family . | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any HL . | Any classical . | Nodular sclerosis . | Lymphocyte-rich . | Mixed cellularity . | Lymphocyte-depleted . | |||||||||||||
| No. . | SIR . | 95% CI . | No. . | SIR . | 95% CI . | No. . | SIR . | 95% CI . | No. . | SIR . | 95% CI . | No. . | SIR . | 95% CI . | No. . | SIR . | 95% CI . | |
| Any HL | 149 | 3.3 | 2.8-3.9 | 63 | 3.0 | 2.3-3.9 | 42 | 3.0 | 2.2-4.1 | 12 | 6.2 | 3.2-11 | 12 | 2.6 | 1.3-4.5 | 1 | 2.9 | 0.1-16 |
| Classical | 70 | 3.9 | 3.0-4.9 | 42 | 3.9 | 2.8-5.3 | 26 | 3.6 | 2.3-5.2 | 9 | 9.8 | 4.5-19 | 10 | 4.3 | 2.1-8.0 | 1 | 6.3 | 0.2-35 |
| Nodular sclerosis | 44 | 3.8 | 2.8-5.1 | 24 | 3.5 | 2.2-5.2 | 22 | 4.6 | 2.9-7.0 | 1 | 1.7 | 0.0-9.5 | 5 | 3.4* | 1.1-7.9 | 0 | ||
| Lymphocyte-rich | 11 | 7.3 | 3.7-13 | 9 | 12 | 5.7-24 | 1 | 2.0 | 0.0-11 | 6 | 81 | 30-177 | 2 | 15 | 1.8-54 | 0 | ||
| Mixed cellularity | 13 | 3.6 | 1.9-6.1 | 7 | 3.6 | 1.5-7.5 | 3 | 2.2 | 0.5-6.5 | 2 | 14 | 1.7-49 | 2 | 5.0 | 0.6-18 | 0 | ||
| Lymphocyte-depleted | 2 | 1.4 | 0.2-5.1 | 2 | 1.9 | 0.2-6.8 | 0 | 0 | 1 | 3.4 | 0.1-19 | 1 | 40 | 1.0-225 | ||||
| Relative’s histology . | HL patient in the family . | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any HL . | Any classical . | Nodular sclerosis . | Lymphocyte-rich . | Mixed cellularity . | Lymphocyte-depleted . | |||||||||||||
| No. . | SIR . | 95% CI . | No. . | SIR . | 95% CI . | No. . | SIR . | 95% CI . | No. . | SIR . | 95% CI . | No. . | SIR . | 95% CI . | No. . | SIR . | 95% CI . | |
| Any HL | 149 | 3.3 | 2.8-3.9 | 63 | 3.0 | 2.3-3.9 | 42 | 3.0 | 2.2-4.1 | 12 | 6.2 | 3.2-11 | 12 | 2.6 | 1.3-4.5 | 1 | 2.9 | 0.1-16 |
| Classical | 70 | 3.9 | 3.0-4.9 | 42 | 3.9 | 2.8-5.3 | 26 | 3.6 | 2.3-5.2 | 9 | 9.8 | 4.5-19 | 10 | 4.3 | 2.1-8.0 | 1 | 6.3 | 0.2-35 |
| Nodular sclerosis | 44 | 3.8 | 2.8-5.1 | 24 | 3.5 | 2.2-5.2 | 22 | 4.6 | 2.9-7.0 | 1 | 1.7 | 0.0-9.5 | 5 | 3.4* | 1.1-7.9 | 0 | ||
| Lymphocyte-rich | 11 | 7.3 | 3.7-13 | 9 | 12 | 5.7-24 | 1 | 2.0 | 0.0-11 | 6 | 81 | 30-177 | 2 | 15 | 1.8-54 | 0 | ||
| Mixed cellularity | 13 | 3.6 | 1.9-6.1 | 7 | 3.6 | 1.5-7.5 | 3 | 2.2 | 0.5-6.5 | 2 | 14 | 1.7-49 | 2 | 5.0 | 0.6-18 | 0 | ||
| Lymphocyte-depleted | 2 | 1.4 | 0.2-5.1 | 2 | 1.9 | 0.2-6.8 | 0 | 0 | 1 | 3.4 | 0.1-19 | 1 | 40 | 1.0-225 | ||||
Example: Risk of nodular sclerosis HL in a first-degree relative of a patient with diagnosis of mixed cellularity HL was 3.4-fold higher than the risk in his/her counterpart in the general population.